KRAS野生型转移性结直肠癌一线进展后继续贝伐珠单抗对比西妥昔单抗联合化疗:UNICANCER PRODIGE18随机临床试验
这项前瞻性、开放标签、多中心、随机2期试验纳入132例KRAS外显子2野生型转移性结直肠癌患者,比较一线贝伐珠单抗联合化疗进展后二线继续贝伐珠单抗(A组)与换用西妥昔单抗(B组)联合化疗的疗效。A组4个月无进展生存率为80.3%,B组为66.7%,中位无进展生存期A组7.1个月、B组5.6个月(HR 0.71,P=0.06),差异未达统计学显著但倾向于继续贝伐珠单抗。
要点
- 4个月无进展生存率A组80.3%(95%CI 68.0%-88.3%),B组66.7%(95%CI 53.6%-76.8%)。
- 中位无进展生存期A组7.1个月 vs B组5.6个月(HR 0.71,95%CI 0.50-1.02,P=0.06),差异未达统计学显著。
- 中位总生存期A组15.8个月 vs B组10.4个月(HR 0.69,95%CI 0.46-1.04,P=0.08),差异未达统计学显著。
核心结论
- PRODIGE18研究结果显示,对于一线贝伐珠单抗联合化疗后进展的RAS野生型转移性结直肠癌患者,二线继续贝伐珠单抗联合化疗交叉方案与换用西妥昔单抗相比差异未达统计学显著,但结果倾向于继续贝伐珠单抗。
研究设计与样本
- 前瞻性、开放标签、多中心、随机2期试验,于2010年12月14日至2015年5月5日开展,共25个中心参与。
- 纳入标准为KRAS外显子2野生型转移性结直肠癌,一线贝伐珠单抗联合氟尿嘧啶及伊立替康或奥沙利铂治疗后疾病进展。
- 共纳入132例患者(女性47例,男性85例;中位年龄63.0岁,范围33.0-84.0岁),所有分析基于改良意向治疗人群。
- 患者随机分入A组(FOLFIRI或mFOLFOX6联合贝伐珠单抗)或B组(FOLFIRI或mFOLFOX6联合西妥昔单抗),二线化疗方案根据一线治疗交叉选择。
主要发现
- 4个月无进展生存率A组为80.3%(95%CI 68.0%-88.3%),B组为66.7%(95%CI 53.6%-76.8%)。
- 中位无进展生存期A组为7.1个月(95%CI 5.7-8.2个月),B组为5.6个月(95%CI 4.2-6.5个月),HR 0.71(95%CI 0.50-1.02,P=0.06)。
- 中位总生存期A组为15.8个月(95%CI 9.5-22.3个月),B组为10.4个月(95%CI 7.0-16.2个月),HR 0.69(95%CI 0.46-1.04,P=0.08)。
- 对95份肿瘤样本进行了KRAS(外显子2、3、4)、NRAS(外显子2、3、4)和BRAF(V600)的中心分析,其中81例患者为KRAS野生型和NRAS野生型肿瘤。
临床怎么用
- 作者认为,对于一线贝伐珠单抗联合化疗后进展的RAS野生型转移性结直肠癌患者,二线继续贝伐珠单抗联合化疗交叉方案与换用西妥昔单抗相比差异未达统计学显著,但结果倾向于继续贝伐珠单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. OBJECTIVE: To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for patients with progression of metastatic colorectal cancer after bevacizumab plus chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: A prospective, open-label, multicenter, randomized phase 2 trial was conducted from December 14, 2010, to May 5, 2015. The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer. All analyses were performed on the modified intent-to-treat population. INTERVENTIONS: Patients were randomized to arm A (FOLFIRI [fluorouracil and folinic acid combined with irinotecan] or modified FOLFOX6 [fluorouracil and folinic acid combined with oxaliplatin] plus bevacizumab) or arm B (FOLFIRI or modified FOLFOX6 plus cetuximab); the second-line chemotherapy regimen was chosen according to first-line treatment (crossover). MAIN OUTCOMES AND MEASURES: The primary end point was the 4-month PFS rate. Secondary end points included safety, objective response rate, overall survival, and PFS. RESULTS: A total of 132 patients (47 women and 85 men; median age, 63.0 years [range, 33.0-84.0 years]; 74 patients with an Eastern Cooperative Oncology Group performance status of 0, 54 patients with a performance status of 1, and 4 patients with unknown performance status) were included at 25 sites. The 4-month PFS rate was 80.3% (95% CI, 68.0%-88.3%) in arm A and 66.7% (95% CI, 53.6%-76.8%) in arm B. The median PFS was 7.1 months (95% CI, 5.7-8.2 months) in arm A and 5.6 months (95% CI, 4.2-6.5 months) in arm B (hazard ratio, 0.71; 95% CI, 0.50-1.02; P = .06), and the median overall survival was 15.8 months (95% CI, 9.5-22.3 months) in arm A and 10.4 months (95% CI, 7.0-16.2 months) in arm B (hazard ratio, 0.69; 95% CI, 0.46-1.04; P = .08). A central analysis of KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), and BRAF (V600) was performed for 95 tumor samples. Eighty-one patients had wild-type KRAS and wild-type NRAS tumors. CONCLUSIONS AND RELEVANCE: The results of the PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study showed a nonsignificant difference but favored continuation of bevacizumab with chemotherapy crossover for patients with wild-type RAS metastatic colorectal cancer that progressed with first-line bevacizumab plus chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01442649 and clinicaltrialsregister.eu identifier: EUDRACT 2009-012942-22.
引用
- Bennouna J, Hiret S, Bertaut A, et al. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30422156. doi:10.1001/jamaoncol.2018.4465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。